RNase L ligand 3 is a RNase L ligand. RNase L ligand 3 can be used for synthesis of F3-PEG8-RiboTAC.

PBRM1/SMARCA2,4-ligand-1 (Compound 4) is a Ligand for Target Protein for PROTAC that binds to PBRM1, SMARCA2, and SMARCA4. PBRM1/SMARCA2,4-ligand-1 is a potent SMARCA4 bromodomain inhibitor. PBRM1/SMARCA2,4-ligand-1 can be used to synthesize PROTAC AU-24118.

TQ-3959 is an orally active BTK PROTAC degrader, with a DC50 of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.

BTK ligand 16 is a BTK ligand that can be used for synthesis of TQ-3959.

JPS004 is a HDAC1-3 PROTAC degrader. JPS004 can induce degradation of HDAC1-3 and induce histone acetylation. JPS004 can induce cancer cells apoptosis. JPS004 can be used for the research of cancer.

OICR-41103N is the negative control form of OICR-41103. OICR-41103 is an effective, selective, cell-active DCAF1 small molecule chemical probe (Ki<2 nM) that targets the DCAF1 WDR domain and replaces the viral Vpr protein.

OICR-41103 is an effective, selective, cell-active DCAF1 small molecule chemical probe that targets the DCAF1 WDR domain and replaces the viral Vpr protein. The binding Ki value of OICR-41103 and DCAF1 is less than 2 nM.

(S,S,S)-AHPC-Me is an E3 ligase ligand. (S,S,S)-AHPC-Me can be used for synthesis of PROTAC (4S)-PROTAC SOS1 degrader-1 diTFA.

FLT3/CHK1 ligand-1 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC FLT3/CHK1 Degrader-1. PROTAC FLT3/CHK1 Degrader-1 is a potent FLT3/CHK1 PROTAC degrader with anti-tumor activity.

IAP ligand 5 is a IAP ligand. IAP ligand 5 can be used to synthesize PROTAC ERα Degrader-2.

E3 ligase Ligand 60 is a ligand for E3 ligase, used for the synthesis of JV8.

(R,S,S)-VH032-Me TFA is an E3 ligase Ligand and can be used for synthesis of dTAGV-1 hydrochloride.

Androgen receptor ligand 2 is a PROTAC target protein ligand that can be used to synthesize the PROTAC Androgen receptor degrader-1.

NP1192 is a potent, selective PROTAC NAT10 degrader that depletes NAT10 protein and inhibits ac4C modification in cancer cells. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research.

DH03 (6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-ethoxyquinoline-3-carbonitrile) is a SARS-CoV-2 MPro ligand. DH03 can be used as a Ligand for Target Protein for PROTAC synthesis, such as PROTAC SARS-CoV-2 Degrader-1.

MTP3 Ligand-linker Conjugate 1 is a conjugate of the MTP3 ligand and the linker. MTP3 Ligand-linker Conjugate 1 can be used for synthesis of PROTAC MTP3 degrade-1.

CRBN ligand-186 is a CRBN-type E3 ubiquitin ligase ligand that can be used to prepare PROTAC.

BION106 is a dihydrofolate reductasethymidylate synthase (DHFR-TS) PROTAC degrader. BION106 exhibits extremely strong anti-malarial activity with a Ki and toxicity of 2.68 nM and 0.2 μM against Plasmodium falciparum, and > 100 μM and 44.2 μM in mammalian cells. BION106 can be used for the study of antimalarial parasites.

E3 ligase Ligand 77 is a CRBN type E3 ubiquitin ligase ligand. E3 ligase Ligand 77 can be used for synthesizing PROTAC, such as PROTAC RET Degrader 1.

EGFR ligand-14 is an EGFR ligand. EGFR ligand-14 can be used for the synthesis of SJF-1521.

E3 ligase Ligand 75 is an E3 ligase ligand. E3 ligase Ligand 75 can be used for synthesis PROTAC K-Ras Degrader-7.

AR ligand 42 is a androgen receptor ligand. AR ligand 42 can be used to synthesize androgen receptor PROTAC degrader ITRI-90.

Pan-KRAS ligand 3 is a pan-KRAS inhibitor. Pan-KRAS ligand 3 can be used for synthesis of PROTAC pan-KRAS degrader-1.

T-01-C7-amide is an E3 ligase ligand-linker conjugate. T-01-C7-amide can be used in the synthesis of PROTAC BRD4 Degrader-36.

G9D-4 (TFA) is a potent PROTAC degrader of G9a, with the DC50 value of 0.1 μM in PANC-1 cells and do not directly perturb GLP protein, with the DC50 of ＞10 μM. G9D-4 (TFA) plays an important role in pancreatic cancer research.

Deoxy-thalidomide-OMe is an E3 ligase ligand. Deoxy-thalidomide-OMe can be used for synthesis of PROTAC LRRK2 Degrader-4.

DDR1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). DDR1 ligand 1 can be used for the synthesis of PROTAC DDR1 degrader-1.

LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research.

AurAP14 is an Aurora A PROTAC degrader (DC50 = 120 nM). AurAP14 shows significant inhibitory activity against various tumor cell lines, with IC50s of 0.294 μM in A549 cells and 0.534 μM in MCF-7 cells. AurAP14 induces apoptosis and arrests A549 cells in the S and G2/M phases. AurAP14 demonstrates anti-tumor efficacy in nude mouse xenograft models of A549 and A549/PTR. AurAP14can be used in the research on the treatment of Aurora A-overexpressing NSCLC.

Brigatinib A is an GID4 ligand. Brigatinib A can be used for synthesizing PROTAC BCR-ABL Degrader-2.